Published in Diabetes Care on August 31, 2010
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015) 1.36
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med (2012) 1.01
Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care (2012) 0.96
Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med (2015) 0.89
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care (2014) 0.86
Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention. Pediatr Diabetes (2015) 0.81
Following the fate of the failing β-cell: new insights from first-phase insulin responses. Diabetes (2013) 0.78
Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes. Diabetes Care (2014) 0.77
Feature ranking based on synergy networks to identify prognostic markers in DPT-1. EURASIP J Bioinform Syst Biol (2013) 0.75
A rule-based prognostic model for type 1 diabetes by identifying and synthesizing baseline profile patterns. PLoS One (2014) 0.75
Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes? Curr Diabetes Rev (2016) 0.75
Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) (2017) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 49.11
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
What is the best predictor of future type 2 diabetes? Diabetes Care (2007) 2.64
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2008) 1.67
Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab (2003) 1.55
Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care (2006) 1.55
Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes (2009) 1.54
A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med (1990) 1.53
Clinical preventive medicine in primary care: background and practice: 2. Delivering primary preventive services. Mayo Clin Proc (2000) 1.46
Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther (2007) 1.36
Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest (1994) 1.34
Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev (2002) 1.30
First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr (2001) 1.29
Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes (1999) 1.26
Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care (2007) 1.22
Clinical preventive medicine in primary care: background and practice: 1. Rationale and current preventive practices. Mayo Clin Proc (2000) 1.19
Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes (1996) 0.96
Risk assessment, prediction and prevention of type 1 diabetes. Pediatr Diabetes (2001) 0.91
Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia (2000) 0.89
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med (2007) 3.58
Diabetic somatic neuropathies. Diabetes Care (2004) 3.39
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2009) 2.91
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab (2008) 2.90
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med (2008) 2.29
Adaptive designs for randomized trials in public health. Annu Rev Public Health (2009) 2.15
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.87
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract (2009) 1.81
Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis (2009) 1.80
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2008) 1.67
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61
New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol (2013) 1.59
Use of SNOMED CT to represent clinical research data: a semantic characterization of data items on case report forms in vasculitis research. J Am Med Inform Assoc (2006) 1.57
Limitations in the cardiac risk reduction provided by coronary revascularization prior to elective vascular surgery. J Vasc Surg (2002) 1.56
Selection of patients for clinical trials: an interactive web-based system. Artif Intell Med (2004) 1.55
Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes (2009) 1.54
Comparing heterogeneous SNOMED CT coding of clinical research concepts by examining normalized expressions. J Biomed Inform (2008) 1.53
Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am J Med (2006) 1.52
Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis (2012) 1.49
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care (2012) 1.45
The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci (2014) 1.44
Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev (2013) 1.43
TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci (2006) 1.40
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
Dose-dependent neurologic abnormalities in workers exposed to 1-bromopropane. J Occup Environ Med (2011) 1.38
Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37
A randomized controlled trial to increase cancer screening among attendees of community health centers. Ann Fam Med (2004) 1.37
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2010) 1.34
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care (2011) 1.30
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol (2005) 1.28
Developmental and vascular risk factors for Alzheimer's disease. Neurobiol Aging (2005) 1.28
The role of behavior observation in measurement systems for randomized prevention trials. Prev Sci (2006) 1.27
Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. Am J Geriatr Psychiatry (2010) 1.27
Multilevel methods for modeling observed sequences of family interaction. J Fam Psychol (2005) 1.27
B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care (2013) 1.25
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care (2007) 1.22
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21
Heterogeneous but "standard" coding systems for adverse events: Issues in achieving interoperability between apples and oranges. Contemp Clin Trials (2008) 1.21
Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab (2008) 1.21
Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care (2011) 1.19
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry (2011) 1.19
Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis (2013) 1.15
Impact of culturally, linguistically, and literacy relevant cancer information among Hispanic farmworker women. J Cancer Educ (2002) 1.14
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol (2010) 1.14
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care (2009) 1.14
The Rare Diseases Clinical Research Network Contact Registry update: features and functionality. Contemp Clin Trials (2012) 1.12
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 1.11